Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins

Nature Methods

Volumn 11, Issue 2, 2014, Pages 149-155

  Kennedy, Jacob J ^a   Abbatiello, Susan E ^b   Kim, Kyunggon ^c   Yan, Ping ^a   Whiteaker, Jeffrey R ^a   Lin, Chenwei ^a   Kim, Jun Seok ^d   Zhang, Yuzheng ^a   Wang, Xianlong ^a   Ivey, Richard G ^a   Zhao, Lei ^a   Min, Hophil ^c   Lee, Youngju ^d   Yu, Myeong Hee ^d   Yang, Eun Gyeong ^d   Lee, Cheolju ^d   Wang, Pei ^a   Rodriguez, Henry ^e   Kim, Youngsoo ^c   Carr, Steven A ^b   Paulovich, Amanda G ^a   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c Seoul National University College of Medicine   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

ARTICLE; BREAST CANCER CELL LINE; EMPIRICAL RESEARCH; FEASIBILITY STUDY; HUMAN; HUMAN GENOME; LARGE SCALE PRODUCTION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STANDARDIZATION;

BIOLOGICAL ASSAY; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEASIBILITY STUDIES; FEMALE; HUMANS; PILOT PROJECTS; PROTEOME; PROTEOMICS; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84895072645     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.2763     Document Type: Article

References (50)

1. Lange, V., Picotti, P., Domon, B. & Aebersold, R. Selected reaction monitoring for quantitative proteomics: A tutorial. Mol. Syst. Biol. 4, 222 (.2008
2. Picotti, P. & Aebersold, R. Selected reaction monitoring-based proteomics: Workflows, potential, pitfalls and future directions. Nat. Methods 9, 555-566 (.2012
3. Pan, S. et al. Mass spectrometry based targeted protein quantification: Methods and applications. J. Proteome Res. 8, 787-797 (.2009
4. Liebler, D.C. & Zimmerman, L.J. Targeted quantitation of proteins by mass spectrometry. Biochemistry 52, 3797-3806 (.2013
5. Hüttenhain, R. et al. Reproducible quantification of cancer-Associated proteins in body fluids using targeted proteomics. Sci. Transl. Med. 4, 142ra94 (.2012
6. Rodriguez, H. et al. Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: An NCI-CPTC initiative perspective. Proteomics Clin. Appl. 4, 904-914 (.2010
7. Addona, T.A. et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 633-641 (.2009
8. Anderson, N.L. et al. A human proteome detection and quantitation project. Mol. Cell. Proteomics 8, 883-886 (.2009
9. Legrain, P. et al. The human proteome project: Current state and future direction. Mol. Cell. Proteomics 10, M111.009993 (.2011
10. Picotti, P. et al. A complete mass-spectrometric map of the yeast proteome applied to quantitative trait analysis. Nature 494, 266-270 (.2013
11. Aebersold, R. et al. The biology/disease-driven human proteome project (.B/D-HPP): Enabling protein research for the life sciences community. J. Proteome Res. 12, 23-27 (.2013
12. Picotti, P. et al. A database of mass spectrometric assays for the yeast proteome. Nat. Methods 5, 913-914 (.2008
13. Remily-Wood, E.R. et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin. Appl. 5, 383-396 (.2011
14. MacLean, B. et al. Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968 (.2010
15. Farrah, T. et al. PASSEL: The PeptideAtlas SRM experiment library. Proteomics 12, 1170-1175 (.2012
16. Abbatiello, S.E., Mani, D.R., Keshishian, H. & Carr, S.A. Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin. Chem. 56, 291-305 (.2010
17. Reiter, L. et al. mProphet: Automated data processing and statistical validation for large-scale SRM experiments. Nat. Methods 8, 430-435 (.2011
18. Chang, C.Y. et al. Protein significance analysis in selected reaction monitoring (.SRM) measurements. Mol. Cell. Proteomics 11, M111.014662 (.2012
19. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (.2012
20. Wood, L.D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113 (.2007
21. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (.2012
22. Kao, J. et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4, e6146 (.2009
23. Neve, R.M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527 (.2006
24. Lehmann, B.D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750-2767 (.2011
25. Witt, A.E. et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J. Proteome Res. 5, 599-610 (.2006
26. Storey, J.D. The positive false discovery rate: A Bayesian interpretation and the q-value. Ann. Stat. 31, 2013-2035 (.2003
27. Naderi, A. et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26, 1507-1516 (.2007
28. Van Laere, S. et al. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clin. Cancer Res. 14, 7452-7460 (.2008
29. Frings, O. et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am. J. Pathol. 182, 2037-2047 (.2013
30. Ménard, S., Fortis, S., Castiglioni, F., Agresti, R. & Balsari, A. HER2 as a prognostic factor in breast cancer. Oncology 61 (.suppl. 2), 67-72 (.2001
31. van t Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (.2002
32. Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239-1246 (.2007
33. Parker, J.S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (.2009
34. Keshishian, H., Addona, T., Burgess, M., Kuhn, E. & Carr, S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6, 2212-2229 (.2007
35. Stahl-Zeng, J. et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 6, 1809-1817 (.2007
36. Halvey, P.J., Ferrone, C.R. & Liebler, D.C. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples. J. Proteome Res. 11, 3908-3913 (.2012
37. Madian, A.G., Rochelle, N.S. & Regnier, F.E. Mass-linked immuno-selective assays in targeted proteomics. Anal. Chem. 85, 737-748 (.2013
38. Whiteaker, J.R. & Paulovich, A.G. Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. Clin. Lab. Med. 31, 385-396 (.2011
39. Ackermann, B.L. Hybrid immunoaffinity-mass spectrometric methods for efficient protein biomarker verification in pharmaceutical development. Bioanalysis 1, 265-268 (.2009
40. Whiteaker, J.R. et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 10, M110.005645 (.2011
41. Anderson, N.L. et al. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (.SISCAPA). J. Proteome Res. 3, 235-244 (.2004
42. Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726-3734 (.2006
43. Prakash, A. et al. Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J. Proteome Res. 9, 6678-6688 (.2010
44. Prakash, A. et al. Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J. Proteome Res. 11, 3986-3995 (.2012
45. MacLean, B., Eng, J.K., Beavis, R.C. & McIntosh, M. General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics 22, 2830-2832 (.2006
46. Vizcaíno, J.A. et al. The PRoteomics IDEntifications (.PRIDE) database and associated tools: Status in 2013. Nucleic Acids Res. 41, D1063-D1069 (.2013
47. Griffin, N.M. et al. Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat. Biotechnol. 28, 83-89 (.2010
48. Krokhin, O.V. Sequence-specific retention calculator. Algorithm for peptide retention prediction in ion-pair RP-HPLC: Application to 300-And 100-Å pore size C18 sorbents. Anal. Chem. 78, 7785-7795 (.2006
49. Storey, J.D. A direct approach to false discovery rates. J. R. Stat. Soc. Series B Stat. Methodol. 64, 479-498 (.2002
50. Tibshirani, R. & Wang, P. Spatial smoothing and hot spot detection for CGH data using the fused lasso. Biostatistics 9, 18-29 (.2008